This week, we are talking about the exit nobody plans for: what the research says actually happens when you stop a GLP-1. Most women find out after the last dose, because the medical system has not written a protocol for stopping. The trials have answers, even if the appointment often doesn't.

☕

THE BIG ONE

FDA-approvedCompounded

The exit nobody plans for

"Insurance dropped it. I have two pens left. Nobody has told me what happens next."

Women are stopping GLP-1s for cost more than any other reason, and mostly stopping without a plan, because the medical system hasn't written one. Compounded versions occupy a particular gray zone: the shortage-era permissions that allowed them have been ending. Here is what the research says happens when any of these medications stop.

THE WEIGHT COMES BACK, AND IT IS NOT A CHARACTER FLAW

In the STEP 1 extension study, people who stopped semaglutide (Wegovy, Ozempic; FDA-approved) regained about two-thirds of what they had lost within a year, and most of the improvements in blood pressure, blood sugar, and cholesterol went with it. In SURMOUNT-4, people switched from tirzepatide (Zepbound, Mounjaro; FDA-approved) to placebo regained a large share of their loss over the following year, while those who stayed on kept losing. These weren't people who "gave up." They were trial participants who stopped on schedule. The biology did the rest.

WHY: THE DRUG WAS MANAGING YOUR APPETITE BIOLOGY, NOT CURING IT

After weight loss, the body defends its old weight. Hunger hormones rise, fullness hormones fall, and energy expenditure drops below what you would predict for the new size. GLP-1s hold that response down while you are on them. Take them away and it comes back, typically within a few weeks as the drug clears. The return of food noise is the first thing women report, and it usually arrives before the scale moves.

WHAT THE RESEARCH HASN'T DONE

The trials studied stopping abruptly. Whether tapering changes the regain curve has no approved protocol and thin data. Whether a lower maintenance dose holds weight is also an open question. Nothing in the labeling covers either, which is exactly why forums are full of women inventing their own versions of both.

WHAT IS SPECIFIC TO WOMEN

Perimenopause independently shifts weight toward the middle and lowers muscle, so stopping at 47 lands on a different body than stopping at 32. Postpartum and breastfeeding are common stop points with almost no data behind them. And cost-driven stopping falls hardest on the women with the least access to follow-up care.

THE FEMALE DATA GAP

The question every woman stopping for cost is asking has no trial designed to answer it.

DEINFLUENCED

WHAT THE EVIDENCE SAYS

Three different things get collapsed into "tolerance," and they have different fixes, which is why the word matters. One: plateaus are the expected math of weight loss, because a smaller body burns less, so the same intake stops producing loss. Two: hunger biology pushes back harder the more weight you lose, which feels like the drug weakening but is your body doing exactly what the trials documented. Three: true pharmacological tolerance, the receptor-level kind, is not established for GLP-1s. Trial participants held their weight at stable doses for years. Calling a plateau "tolerance" leads people to self-escalate or quit. Naming what is actually happening leads to a conversation with a prescriber.

ASK A CLINICIAN

There are four things worth bringing to that appointment. First, ask whether there is any path to continuing. Manufacturer savings programs exist for both semaglutide and tirzepatide (both FDA-approved), some plans cover a different formulation, and appeals do sometimes succeed. It is worth asking before assuming the door is closed.

Second, ask your prescriber what to expect in the weeks after stopping. The return of appetite, sometimes called food noise, typically arrives within a few weeks of the last dose, often before the scale moves. Knowing it is biology, not a personal failure, changes how you experience it.

Third, ask what your prescriber wants to monitor and when. The improvements in blood pressure and blood sugar that came with weight loss can reverse after stopping. Someone should be watching, and it is reasonable to ask who and how often.

Fourth, ask about a plan for the habits that helped alongside the medication. Those travel with you regardless of what happens with coverage. What is worth keeping, and what does your prescriber want to track going forward? That conversation is more useful than adjusting or rationing doses on your own.

Mais, PharmD

Medical Reviewer, Pep in Her Step

ON THE RADAR

This issue was medically reviewed by Mais, PharmD.
Pep in Her Step is education, not medical advice.
Talk to your prescriber before doing anything peptide-shaped.
We don't sell peptides and never will.

Forwarded this? Get it weekly at pepinherstep.com